CXCR4 intracellular protein promotes drug resistance and tumorigenic potential by inversely regulating the expression of Death Receptor 5

Chemokine receptor CXCR4 overexpression in solid tumors has been strongly associated with poor prognosis and adverse clinical outcome. However, blockade of CXCL12-CXCR4 signaling axis by inhibitors like Nox-A12, FDA approved CXCR4 inhibitor drug AMD3100 have shown limited clinical success in cancer...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cell Death Dis
Autors principals: Nengroo, Mushtaq A., Maheshwari, Shrankhla, Singh, Akhilesh, Verma, Ayushi, Arya, Rakesh K., Chaturvedi, Priyank, Saini, Krishan K., Singh, Anup K., Sinha, Abhipsa, Meena, Sanjeev, Gupta, Annapurna, Mishra, Anjali, Sarkar, Jayanta, Datta, Dipak
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8106681/
https://ncbi.nlm.nih.gov/pubmed/33966046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-021-03730-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars